MEI Pharma Inc
For the period ended Jun 30, 2024. Filed Sep 19, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Sep 19, 2024
LITS$0.95-6.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
(In thousands, except per share amounts)
| For the Fiscal Year Ended June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Revenues: | ||
| Revenue from customers | $752 | $48,816 |
| Revenue from collaboration agreements | 64,545 | — |
| Total revenues | 65,297 | 48,816 |
| Operating expenses: | ||
| Research and development | 16,561 | 52,450 |
| General and administrative | 23,295 | 33,130 |
| Impairment of long-lived assets | 10,899 | — |
| Total operating expenses | 50,755 | 85,580 |
| Income (loss) from operations | 14,542 | (36,764) |
| Other income (expense): | ||
| Change in fair value of warrant liability | — | 1,603 |
| Interest and dividend income | 3,277 | 3,345 |
| Other expense, net | (41) | (22) |
| Total other income, net | 3,236 | 4,926 |
| Net income (loss) | $17,778 | $(31,838) |
| Net income (loss) per share - basic and diluted | $2.67 | $(4.78) |
| Weighted-average shares used in computing net income (loss) per share - basic and diluted | 6,663 | 6,663 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.